Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
VISTA-Rehab: A resource for stroke rehabilitation trials
Myzoon Ali,Ann Ashburn,Audrey Bowen,Eric E. Brodie,Susan Corr,Avril Drummond,Judi Edmans,John R.F. Gladman,Lalit Kalra,Peter Langhorne,Kennedy R. Lees,Nadina B. Lincoln,Pip Logan,Gillian Mead,E. Patchick,Alex Pollock,Valerie M. Pomeroy,Catherine Sackley,Katherina S. Sunnerhagen,Paulette van Vliet,Marion F Walker,Marian C. Brady +21 more
TL;DR: An archive of stroke rehabilitation trials (VISTA-Rehab) is developed to act as a resource to help trialists model and design future rehabilitation studies and expand the Virtual International Stroke Trials Archive to include rehabilitation trials.
15
Clinical Pharmacology of CNS 1102 in Volunteers
TL;DR: CNS 1102 is neuroprotective in preclinical models of stroke when administered as pretreatment or up to 60 minutes postischemia, and has potential for treatment of acute stroke or traumatic brain injury in man.
15
Letter by Kerr and Lees Regarding Article, “Country Comparisons of Human Stroke Research Since 2001: A Bibliometric Study”
Daniel M. Kerr,Kennedy R. Lees +1 more
TL;DR: An international comparison of the quantity and quality of stroke research from 2001 to 2011 found that by far the leading producer of strokeResearch articles was the United States followed by Japan, the United Kingdom, and Germany.
14
Tissue angiotensin converting enzyme inhibition. Relevant to clinical practice
TL;DR: Evidence and other data suggest that inhibition of tissue ACE may be as, or more, important than its effects on the more easily measured circulating ACE, and raises the question of whether there are differences among ACE inhibitors in their selectivity for one or more organ systems.
14
Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions
Z. Hussein,I. J. Fraser,Kennedy R. Lees,Keith W. Muir,M. W. Lunnon,S. F. Hobbiger,John Posner +6 more
TL;DR: The pharmacokinetics of 619C89 are independent of dose in acute stroke patients and those of 78C90 are elimination rate-limited and are also dose-independent, according to the ANOVA results.
14